Covance adding mass spec for biosimilars

By Nick Taylor

- Last updated on GMT

Related tags: Mass spectrometry, Covance

Covance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.

Efforts to create a pathway for biosimilars in the US have attracted generics companies, big biopharm and virtual biotechs. This has created opportunities for contract research organisations (CROs).

What’s really big right now is the biosimilar market. So what we’re developing is the ability to do high-level structural characterisation​”, Ray Kaiser, chief scientific officer, biotechnology at Covance, told Outsourcing-Pharma.

Covance is adding expertise in mass spectrometry and physical chemical analyses to help clients assess the comparability of biosimilars to innovator molecules. Some of these clients are virtual biotechs that need more guidance through the drug development process than larger companies.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more